|
Pendahuluan: Tesis ini bertujuan untuk mengetahui efek myelosupresi padapasien kanker ovarium dengan kemoterapi ajuvan carboplatin dan paclitaxel diRSUPN dr. Cipto Mangunkusumo melalui analisis kadar hemoglobin, leukosit,dan trombosit. Kemoterapi ajuvan kombinasi carboplatin dan paclitaxelmerupakan rejimen kemoterapi yang paling efektif pada kanker ovarium. Namunpemberian kemoterapi tersebut memiliki efek samping myelosupresi sepertianemia, neutropenia, dan trombositopenia yang berdampak besar terhadapkualitas hidup pasien. Metode: Penelitian ini adalah penelitian hystorical cohort yang dilaksanakan diRSUPN Dr. Cipto Mangunkusumo dengan mengambil sampel penelitian pasienkanker ovarium yang mendapatkan kemoterapi ajuvan dengan carboplatin danpaclitaxel sebanyak enam seri mulai dari Januari 2010 sampai dengan Desember2014. Hasil: Dari 41 subjek penelitian yang memenuhi kriteria inklusi didapatkan usiapasien berkisar antara 25 sampai dengan 64 tahun (median: 49 tahun), terbanyakadalah multipara (43,9%), premenopause (61,0%), dengan stadium terbanyakadalah stadium IIIC (58,5%), histopatologi terbanyak adalah kistadenokarsinomaserosum (39,0%), dan sebagian besar berdiferensiasi sedang (48,8%). Kesimpulan: Sebagai kesimpulan didapatkan penurunan kadar hemoglobin, leukosit, dan trombosit yang bermakna pasca kemoterapi setiap seri (p < 0,001). ;Background: The objective of this study was to obtain the myelosupressioneffect on ovarian cancer patient with carboplatin and paclitaxel adjuvantchemotherapy based on haemoglobin, leucocyte, and thrombocyte level.Carboplatin and paclitaxel combination as an adjuvant chemotherapy is the mosteffective regiment for ovarian cancer. Otherwise this regiment hasmyelosuppression effect (hematologic toxicity) as anemia, neutropenia, andthrombocytopenia which have impact on quality of life of the patients. Methods: This is an hystorycal cohort study on ovarian caner patients whounderwent six series of adjuvant chemotherapy from January 2010 untilDecember 2014 at RSUPN Dr. Cipto Mangunkusumo. Results: From 41 patients range at 25 until 64 years old (median: 49 years), mostof them are multiparity (43,9%), premenopausal women (61,0%), with the largeststadium was IIIC (58,5%), the largest pathologic type was serouscystadenocarcinoma (39,0%) and most of them are intermediate differentiation(48,8%). Conclusions: As a conclusion there was a significantly decreased of haemoglobin, leucocyte, and thrombocyte levels after adjuvant chemotherapy on every single cycle (p<0,001). ;Background: The objective of this study was to obtain the myelosupressioneffect on ovarian cancer patient with carboplatin and paclitaxel adjuvantchemotherapy based on haemoglobin, leucocyte, and thrombocyte level.Carboplatin and paclitaxel combination as an adjuvant chemotherapy is the mosteffective regiment for ovarian cancer. Otherwise this regiment hasmyelosuppression effect (hematologic toxicity) as anemia, neutropenia, andthrombocytopenia which have impact on quality of life of the patients. Methods: This is an hystorycal cohort study on ovarian caner patients whounderwent six series of adjuvant chemotherapy from January 2010 untilDecember 2014 at RSUPN Dr. Cipto Mangunkusumo. Results: From 41 patients range at 25 until 64 years old (median: 49 years), mostof them are multiparity (43,9%), premenopausal women (61,0%), with the largeststadium was IIIC (58,5%), the largest pathologic type was serouscystadenocarcinoma (39,0%) and most of them are intermediate differentiation(48,8%). Conclusions: As a conclusion there was a significantly decreased of haemoglobin, leucocyte, and thrombocyte levels after adjuvant chemotherapy on every single cycle (p<0,001). |
SP-Better Versi Paniroi.pdf :: Unduh